ACT-777991

• Description :

  ACT-777991 is an orally active and selective CXCR3 antagonist. ACT-777991 has microsomes and hepatocytes stability across animal models. ACT-777991 inhibits the migration of activated T cells toward CXCL11[1].

• CAS Number :

  [1967811-46-6]

• UNSPSC :

  12352005

• Target :

  CXCR

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/act-777991.html

• Purity :

  99.86

• Solubility :

  10 mM in DMSO

• Smiles :

  OCC[C@@H](N(C(CN1C=NC(C)=N1)=O)CC2)CN2C(SC(C(F)(F)F)=N3)=C3C4=CN=C(C(F)(F)F)N=C4

• Molecular Formula :

  C20H20F6N8O2S

• Molecular Weight :

  550.48

• References & Citations :

  [1]Meyer EA, et al. Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies. J Med Chem. 2023 Mar 23;66 (6) :4179-4196.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• Isoform :

  CXCR3